Your browser is no longer supported. Please, upgrade your browser.
AMRN Amarin Corporation plc monthly Stock Chart
Amarin Corporation plc
Index- P/E- EPS (ttm)-0.07 Insider Own1.00% Shs Outstand373.75M Perf Week-61.90%
Market Cap1.95B Forward P/E9.49 EPS next Y0.55 Insider Trans0.00% Shs Float120.58M Perf Month-67.42%
Income-22.60M PEG- EPS next Q-0.08 Inst Own46.60% Short Float35.14% Perf Quarter-75.75%
Sales429.80M P/S4.54 EPS this Y83.10% Inst Trans-11.94% Short Ratio3.67 Perf Half Y-64.30%
Book/sh1.63 P/B3.20 EPS next Y711.10% ROA-3.60% Target Price28.45 Perf Year-74.32%
Cash/sh1.72 P/C3.03 EPS next 5Y24.70% ROE-6.40% 52W Range3.95 - 26.12 Perf YTD-75.65%
Dividend- P/FCF- EPS past 5Y27.30% ROI-3.80% 52W High-80.02% Beta1.28
Dividend %- Quick Ratio3.20 Sales past 5Y51.30% Gross Margin77.70% 52W Low32.15% ATR1.89
Employees965 Current Ratio3.50 Sales Q/Q85.40% Oper. Margin-5.60% RSI (14)29.39 Volatility13.68% 14.63%
OptionableYes Debt/Eq0.09 EPS Q/Q118.40% Profit Margin-5.30% Rel Volume5.04 Prev Close4.98
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout- Avg Volume11.56M Price5.22
Recom2.20 SMA20-55.14% SMA50-66.24% SMA200-70.48% Volume58,197,819 Change4.82%
Mar-31-20Upgrade Oppenheimer Underperform → Perform
Mar-31-20Downgrade Jefferies Buy → Hold $30 → $4
Mar-31-20Downgrade Goldman Buy → Neutral
Mar-13-20Upgrade Goldman Neutral → Buy $28
Mar-02-20Initiated Cowen Outperform $23
Feb-18-20Upgrade Citigroup Neutral → Buy $27 → $24
Jan-06-20Initiated JP Morgan Neutral $22
Dec-16-19Downgrade Stifel Buy → Hold
Nov-20-19Initiated Oppenheimer Underperform $7
Nov-18-19Downgrade Citigroup Buy → Neutral
Nov-15-19Reiterated SVB Leerink Outperform $26 → $29
Oct-31-19Initiated Aegis Capital Buy $23
Oct-15-19Initiated Goldman Neutral $17
Aug-14-19Initiated SVB Leerink Outperform $26
Jul-09-19Reiterated Jefferies Buy $30
Jun-17-19Initiated ROTH Capital Buy $31
Mar-22-19Initiated Stifel Buy $27
Nov-14-18Upgrade Citigroup Neutral → Buy
Nov-02-18Downgrade Citigroup Buy → Neutral
Jun-27-17Resumed Cantor Fitzgerald Overweight
Apr-02-20 01:30PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses In Excess of $1,000,000 to Contact the Firm ACCESSWIRE
09:55AM  Is Amarin (AMRN) Stock a Solid Choice Right Now? Zacks
Apr-01-20 12:15PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $500,000 to Contact the Firm ACCESSWIRE +24.50%
11:01AM  Judges Record Looks Unpromising for Amarins Appeal; Analyst Remains Bullish TipRanks
Mar-31-20 06:19PM  INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire -70.54%
04:30PM  Amarin Stock Melts Down After Losing Patent Battle For Heart Drug Investor's Business Daily
12:00PM  Judicial Ruling Guts Amarin (AMRN) Stock; Whats Next? TipRanks
10:12AM  Amarin's Stock Plunges Following Unfavorable Patent Ruling Zacks
08:50AM  Amarin Investors Who Lost Money Should Contact Block & Leviton: The Firm Is Investigating Securities Fraud at the Company GlobeNewswire
08:49AM  Amarin's stock plummets on heavy volume after court rules in favor of makers of generic Vascepa MarketWatch
08:26AM  The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions Benzinga
07:20AM  Halliburton Soars, Amarin Slumps as Chinese Data Show Signs of Life
07:00AM  Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiologys Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) GlobeNewswire
03:21AM  Amarin Shares Drop 67% As Court Invalidates Its Heart Drug Patent For Vascepa Benzinga
Mar-30-20 06:37PM  Amarin Shares Crushed After Judge Rules Heart Drug Patents Invalid: Report
06:25PM  Amarin Comments on Ruling in VASCEPA® ANDA Litigation GlobeNewswire
11:45AM  Eicosapentaenoic Acid (EPA) Levels From VASCEPA® (Icosapent Ethyl) in REDUCE-IT® Strongly Correlated with Cardiovascular Outcomes GlobeNewswire
Mar-25-20 09:29AM  Do Options Traders Know Something About Amarin (AMRN) Stock We Don't? Zacks
Mar-22-20 11:01PM  Hedge Funds Have Never Been This Bullish On Amarin Corporation (AMRN) Insider Monkey
Mar-20-20 08:10AM  Even If It Hurts Amarin Stock, Reducing the Vascepa Sales Push Is Smart InvestorPlace -7.72%
Mar-18-20 08:51AM  U.S. companies begin delaying clinical trials due to coronavirus outbreak Reuters
Mar-17-20 09:40AM  Goldman Sachs: 3 Stocks to Snap up on the Dip TipRanks
Mar-16-20 08:00AM  Eight Data Presentations Relevant to VASCEPA® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented at the American College of Cardiologys 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC), March 28 30 GlobeNewswire -18.25%
Mar-15-20 01:56PM  Amarin Takes Proactive Steps to Support Public Health Priorities GlobeNewswire
Mar-06-20 06:50AM  Amarin Stock Looks Like a Heart-Healthy Buy on the Dip InvestorPlace
Mar-04-20 10:49AM  The Charts of Amarin Tell Us That a Close Below $14 Is Key
Mar-01-20 08:38AM  Introducing Amarin (NASDAQ:AMRN), The Stock That Soared 726% In The Last Five Years Simply Wall St.
Feb-28-20 02:48PM  Look Anywhere but Acasti Pharma Stock for Opportunity InvestorPlace
10:07AM  Confounding Decline Creates an Opportunity in Amarin Stock InvestorPlace
Feb-27-20 02:05PM  PreMarket Prep Stock Of The Day: Amarin Benzinga -9.83%
Feb-26-20 04:46PM  Edited Transcript of AMRN earnings conference call or presentation 25-Feb-20 9:30pm GMT Thomson Reuters StreetEvents -7.03%
09:16AM  Amarin's (AMRN) Q4 Earnings and Sales Surpass Estimates Zacks
Feb-25-20 04:05PM  Amarin Reports Record Fourth Quarter and Full Year 2019 Financial Results and Provides Update on Operations GlobeNewswire
04:05PM  Amarin beats quarterly revenue estimates on strong Vascepa uptake Reuters
08:28AM  The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement Benzinga
Feb-21-20 05:50PM  Amarin (AMRN) Gains As Market Dips: What You Should Know Zacks
Feb-20-20 09:25AM  What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
06:00AM  Amarin to Present at Two Upcoming Investor Conferences GlobeNewswire
Feb-19-20 04:15PM  Amarin To Report Fourth Quarter and Full Year 2019 Results and Host Conference Call on February 25, 2020 GlobeNewswire
08:34AM  Is the Options Market Predicting a Spike in Amarin (AMRN) Stock? Zacks
Feb-18-20 08:48AM  Buy Amarin Stock Because It Has Fallen Far Enough, Analyst Says
Feb-14-20 01:44PM  Vascepa Growth Will Power Amarin Stock Way Higher in 2020 InvestorPlace
11:41AM  Risks Remain, but Amarin Stock Is a Buy at Todays Prices InvestorPlace
Feb-12-20 02:03PM  Will Positive Patent News Send Amarin Stock Higher? Analysts Fight It Out TipRanks
Feb-11-20 05:45PM  Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-06-20 09:26PM  Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval GlobeNewswire
Feb-05-20 05:50PM  Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know Zacks
Jan-30-20 05:45PM  Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know Zacks
01:44PM  Amarin Stock's Outlook Not for the Faint of Heart
Jan-28-20 01:48PM  5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts Kiplinger
06:30AM  HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl) CNW Group
Jan-23-20 09:31AM  A Tale of 3 Healthcare Stocks 2 to Buy, and 1 to Sell TipRanks
Jan-17-20 11:07AM  Does Acasti Stock Have a Future? InvestorPlace
06:30AM  Why Amarin Stock Is Poised for a Healthy 2020 InvestorPlace
Jan-16-20 05:37AM  Does Amarin Corporation plc's (NASDAQ:AMRN) CEO Pay Matter? Simply Wall St.
Jan-15-20 05:45PM  Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know Zacks
Jan-14-20 09:46AM  AstraZeneca to End Phase III Study on Fish Oil Heart Drug Zacks
Jan-13-20 04:22PM  This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled Investor's Business Daily
02:31PM  Amarin's stock surges, as rival drugs from AstraZeneca, Acasti disappoint MarketWatch
11:07AM  Amarin Stock Is Surging as Rival Makers of Fish-Oil Heart Drugs Fall Short
09:40AM  This Biotech Stock Is Flying High After Rival Heart Drugs Stumbled Investor's Business Daily
06:00AM  Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk GlobeNewswire
Jan-10-20 06:08PM  AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down Zacks -5.20%
01:02PM  Amarin Stock Bouncing Back After Revised Results and 2020 Guidance InvestorPlace
12:08PM  7 Healthcare Stocks to Buy or Sell As Pricing Pressures Mount InvestorPlace
10:59AM  All Bets Are Off for Amarin Stock InvestorPlace
08:40AM  BioMarin (BMRN) Catches Eye: Stock Jumps 5.8% Zacks
Jan-09-20 04:47PM  Applied Therapeutics Up on Positive Galactosemia Study Data Zacks
Jan-08-20 10:04AM  Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease Zacks
09:28AM  How Did Amarin Corporation plc (AMRN) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
09:00AM  Why Amarin (AMRN) Stock Might be a Great Pick Zacks
08:53AM  Amarin Posts '19 Preliminary Results, Gives 2020 Expense View Zacks
Jan-07-20 01:53PM  Amarin Corporation (AMRN): All Eyes on Vascepa 2020 Sales TipRanks -5.42%
10:55AM  Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% Higher Zacks
09:19AM  aTyr (LIFE) Surges on Collaboration Deal With Kyorin Pharma Zacks
08:45AM  Bullish Looking Amarin Is Set to More Than Double From Current Levels
06:37AM  Amarin raises 2019 revenue outlook, to double sales team as it 'aggressively' launches Vascepa in the U.S. MarketWatch
06:00AM  Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook GlobeNewswire
Jan-06-20 05:50PM  Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know Zacks
03:30PM  HLS Therapeutics Announces 8 Years of Data Protection for Vascepa® CNW Group
09:03AM  Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock? Zacks
06:00AM  Amarin to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-20 06:00AM  Amarin Risks Getting Exposed as a Paper Tiger InvestorPlace
Jan-02-20 09:16AM  Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day Zacks
08:46AM  The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe Benzinga
06:00AM  VASCEPA® Approved in Canada to Reduce the Risk of Cardiovascular Events GlobeNewswire
Dec-31-19 01:00PM  HLS Therapeutics Announces Health Canada Approval for Vascepa® to Reduce the Risk of Cardiovascular Events CNW Group
12:01PM  Vascepas Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock InvestorPlace
09:35AM  Health for Patients, Wealth for Investors: Watch Amarin Stock Closely InvestorPlace
08:45AM  3 Biotech Stocks Likely to Maintain Solid Momentum in 2020 Zacks
08:22AM  Heres Why Amarin Stock Slumped Despite the FDA Approval InvestorPlace
Dec-27-19 11:30AM  Has Amarin Corporation (AMRN) Outpaced Other Medical Stocks This Year? Zacks
Dec-24-19 07:30AM  10 Biotech M&A Targets Under The Scanner For 2020 Benzinga
Dec-21-19 11:08AM  Amarins fish-oil pill is now available to millions more patients, but its still no Lipitor MarketWatch
Dec-20-19 04:41AM  Amarin Stock is at Sky-High Levels Already Assumes All the Good News InvestorPlace
Dec-19-19 12:00PM  Amarin (AMRN) is a Great Momentum Stock: Should You Buy? Zacks
10:13AM  The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals Zacks
Dec-18-19 02:27PM  Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More Zacks
Dec-17-19 07:56AM  The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO Benzinga -6.73%
Dec-16-19 02:28PM  Analyst: With FDA Approval Already Priced In, Avoid Amarin (AMRN) Stock TipRanks -5.14%
Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.